Hepatitis C virus transmission among people who inject drugs in rural United States: mathematical modeling study using stochastic agent-based network simulation - Scorecard - MDSpire
Advertisement
Hepatitis C virus transmission among people who inject drugs in rural United States: mathematical modeling study using stochastic agent-based network simulation
Clinical Scorecard: Modeling Hepatitis C Virus Spread Among Injection Drug Users in Rural America: A Stochastic Agent-Based Network Simulation Approach
At a Glance
Category
Detail
Condition
Hepatitis C virus (HCV) infection
Key Mechanisms
Transmission via injection equipment sharing among people who inject drugs (PWID) through social and injection networks
Target Population
People who inject drugs (PWID) in rural America, specifically rural Appalachia
Care Setting
Community and public health settings focusing on harm reduction and HCV prevention among PWID
Key Highlights
PWID account for approximately 67% of new HCV infections in the US, with increasing incidence driven by the opioid crisis.
HCV transmission dynamics are strongly influenced by injection equipment-sharing network properties such as prevalence, average number of partners, and homophily.
Higher HCV prevalence and network connectivity reduce heterogeneity in infection risk and increase overall incidence among PWID.
Guideline-Based Recommendations
Diagnosis
Use HCV antibody testing among PWID populations to identify infection prevalence and incidence.
Management
Implement harm reduction programs to reduce injection equipment sharing.
Utilize direct-acting antiviral (DAA) treatments for HCV infection, which are highly effective and require 8-12 weeks of oral therapy.
Monitoring & Follow-up
Monitor network properties such as average number of injection partners and HCV prevalence to inform intervention strategies.
Track incidence and heterogeneity of HCV infection risk within PWID networks.
Risks
Injection equipment sharing remains the dominant risk factor for HCV transmission among PWID.
Higher network connectivity and homophily in infection status increase transmission risk.
Patient & Prescribing Data
People who inject drugs in rural settings with varying network structures and HCV prevalence.
DAA treatments are effective but costly; understanding network transmission dynamics can optimize targeting of treatment as prevention strategies.
Clinical Best Practices
Incorporate social network analysis to identify high-risk subgroups within PWID populations for targeted interventions.
Combine harm reduction efforts with DAA treatment to reduce HCV incidence effectively.
Consider heterogeneity in injection networks when designing and implementing HCV prevention programs.
by Lin Zhu, Jennifer R Havens, Abby E Rudolph, April M Young, Golnaz Eftekhari Yazdi, William W Thompson, Liesl M Hagan, Liisa M Randall, Jianing Wang, Rebecca Earnest, Shayla Nolen, Benjamin P Linas, Joshua A Salomon
